title: Hepatic resection of giant cavernous hemangioma of the liver.
abstract: Surgical treatment of giant hemangioma of the liver is still controversial. The aim of this study is to examine the efficacy of hepatic resection for giant hemangioma of the liver. Twenty patients with giant cavernous hemangioma of the liver were treated by hepatic resection. The mean diameter of the hemangiomas was 13.9 cm (range, 6.5-30 cm). The surgical outcome was reviewed retrospectively. Major hepatectomy was performed in 14 patients and minor hepatectomy in 6 patients. Complications occurred in 7 of the 20 patients treated by hepatic resection. At a mean follow-up of 79 months (range, 12-173 months), 18 patients were symptom free whereas 2 patients had died--one died of pneumonia at 2 years and the other died of gastric cancer 6 years after surgery. Mean intraoperative hemorrhage and blood transfusion in all patients was 4,343 mL (range, 270-24,000 mL) and 1,860 mL (range, 0-8,800 mL) respectively. In the seven patients with preoperative high levels of fibrin degradation products (FDP), mean intraoperative hemorrhage and blood transfusion were markedly higher (9,371 mL and 3,714 mL respectively) than in the 13 patients without abnormal FDP (1,603 mL and 900 mL respectively). Preoperative hematologic status returned to normal after operation in all patients. Hepatic resection is a useful treatment for giant cavernous hemangioma of the liver. More careful management to reduce intraoperative hemorrhage is recommended to increase the safety of surgery, particularly in patients with preoperative abnormal FDP.
authors.affiliation: Second Department of Surgery, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Hanazaki
authors.forename: S
authors.initials: S
authors.lastname: Kajikawa
authors.forename: A
authors.initials: A
authors.lastname: Matsushita
authors.forename: T
authors.initials: T
authors.lastname: Monma
authors.forename: N
authors.initials: N
authors.lastname: Koide
authors.forename: Y
authors.initials: Y
authors.lastname: Nimura
authors.forename: K
authors.initials: K
authors.lastname: Yazawa
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Nishio
authors.forename: W
authors.initials: W
authors.lastname: Adachi
authors.forename: J
authors.initials: J
authors.lastname: Amano
mesh_terms: D000328:Adult; D000368:Aged; D001778:Blood Coagulation Disorders / Q000097:blood / Q000150:complications / Q000175:diagnosis; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005500:Follow-Up Studies; D006392:Hemangioma, Cavernous / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D006498:Hepatectomy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000150:complications / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D005338:Fibrin Fibrinogen Degradation Products